indication

Psychosis

Competitive landscape projected to Individual placement and support (vocational rehabilitation)’s launch window

as of 2026-07-01
Competitive set
16
14 approved · 2 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
113 events
2020
2024
2028
2032
2036
2040
2044
2048
today
Individual placement and support (vocational rehabilitation) launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 48 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugNot Yet Recruiting
Aripiprazole
US-approved 2002 · ABILIFY
Phase 47 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 43 trials
OwnerAstraZeneca
Protection—
drugRecruiting
Clozapine
US-approved 1989 · Clozaril
Phase 43 trials
OwnerShanghai Mental Health Center
Protection2028
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 43 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Asenapine
US-approved 2009 · SAPHRIS
Phase 32 trials
OwnerOrganon and Co
Protection2033
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 42 trials
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugUnknown
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 42 trials
OwnerEli Lilly and Company
Protection2041
drugWithdrawn
Lurasidone
US-approved 2010 · Latuda
—1 trial
OwnerSumitomo Pharmaceuticals America
Protection2031
drugWithdrawn
Pimavanserin
US-approved 2016 · NUPLAZID
Phase 21 trial
OwnerACADIA Pharmaceuticals Inc.
Protection2039
drugUnknown
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 41 trial
OwnerJohnson & Johnson
Protection2041
drugWithdrawn
Lumateperone (Caplyta)
US-approved 2019 · CAPLYTA
Phase 41 trial
OwnerIntra-Cellular Therapies, Inc.
Protection2040
drugRecruiting
Brexpiprazole (Rexulti)
US-approved 2015 · Rexulti
—1 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2033
drugRecruiting
Xanomeline-trospium (Cobenfy)
US-approved 2024 · Cobenfy
Phase 31 trial
OwnerKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Protection2039
drugNot Yet Recruiting
Cannabidiol
Pipeline · Phase 3
Phase 32 trials
OwnerCentral Institute of Mental Health, Mannheim
Protection—
drugCompleted
Minocycline
Pipeline · Phase 2
Phase 21 trial
OwnerShalvata Mental Health Center
Protection—

Market size

prevalence as a range, not a number